Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
EPR Properties Q4 and Year-End 2025 Earnings Call - Pivoting Hard Into Experiential Assets With $400M-$500M 2026 Investment Plan
EPR closed 2025 with steady rent coverage, modest per-share growth, and a clear pivot: double down on experiential assets. FFO as adjusted rose about 5% year over year, AFFO rose about 6%, the portfol...
- EPR is accelerating experiential investments, guiding $400 million to $500 million of capital deployment in 2026 versus $288.5 million in 2025.
- FFO as adjusted per share rose to $5.12 for 2025, up about 5.1% year over year; AFFO per share rose about 6.2% to $5.14.
- Q4 FFO/AFFO per share were $1.30, increases of roughly 5.7% and 6.6% respectively versus the prior year quarter.
- +12 more takeaways
TG Therapeutics Q4 2025 Earnings Call - BRIUMVI Scales to $616M, Readouts This Year Could Simplify Treatment
TG Therapeutics closed 2025 with clear commercial traction for BRIUMVI, delivering roughly $616 million in total revenue and $594 million of U.S. net sales. Management says physician uptake, strong pe...
- Total 2025 global revenue about $616 million, with roughly $594 million in U.S. BRIUMVI net sales. Q4 U.S. BRIUMVI net sales were $182.7 million and total Q4 net product revenue was $189.1 million (including $6.4 million to Neuraxpharm).
- Fourth quarter growth was strong: ~92% year-over-year and ~20% sequential growth versus Q3, management says driven by new patient starts, prescriber expansion, and strong persistence.
- Six-year open-label ULTIMATE I/II data presented at ECTRIMS showed nearly 90% of patients free from 24-week confirmed disability progression after six years, a very low relapse rate (characterized by management as one relapse per 83 years of treatment), and no new safety signals. Those data are a core commercial argument.
- +11 more takeaways
Codere Online Q4 2025 Earnings Call - Record Net Gaming Revenue, Mexico-Led Growth and 2026 Profit Guidance
Codere Online closed 2025 on a high note, reporting a company record Net Gaming Revenue for the year of EUR 224 million and a Q4 NGR of EUR 60.7 million, up 15% year on year. Profitability is improvin...
- Company posted record FY 2025 Net Gaming Revenue of EUR 224 million; Q4 NGR reached EUR 60.7 million, the highest quarterly NGR in company history.
- Adjusted EBITDA for full year 2025 was EUR 13.8 million, more than double 2024’s EUR 6.4 million; Q4 Adjusted EBITDA was EUR 6.7 million, up EUR 4.8 million YoY.
- Q4 EBITDA margin improved to about 11%, versus under 4% in Q4 2024, showing operating leverage as NGR scales.
- +11 more takeaways
BioCryst Pharmaceuticals Q4 2025 Earnings Call - ORLADEYO drove record profitability as navenibart aims to own HAE prophylaxis
BioCryst closed 2025 with ORLADEYO revenue of $601.8 million, a 38% year on year increase and 43% growth excluding the divested European business, and posted a non-GAAP operating profit of $214 millio...
- ORLADEYO delivered full-year 2025 revenue of $601.8 million, up 38% year on year, and up 43% when excluding the European business sold in October.
- BioCryst reported a record non-GAAP operating profit of $214 million in 2025, a 198% increase year on year after stripping out Europe and one-time items.
- Management is repositioning BioCryst as a profitable, rare disease company focused on a portfolio approach to HAE prophylaxis, not a single-product defense.
- +16 more takeaways
Arbe Robotics Q4 2025 Earnings Call - Strategic Pivot to Defense, Robotaxi and Non-Auto Markets as CEO Transition Extends Runway
Arbe used this quarter to acknowledge what many already felt, and then acted. Management is broadening the commercial focus away from a sole reliance on Western passenger OEMs toward faster-adopting m...
- Strategic pivot: Arbe is broadening focus beyond Western passenger OEMs to prioritize Chinese OEMs, defense, homeland security, robotaxi/robotruck, marine safety and smart infrastructure where adoption cycles are shorter.
- Leadership change: Ram Machness will become CEO on April 1, 2026. Kobi Marenko transitions to President to focus on long-term strategy and defense partnerships.
- Balance sheet strengthened: Cash and equivalents were $45.0 million at December 31, 2025, and the company raised $18.5 million in an underwritten public offering in January 2026.
- +15 more takeaways
Warby Parker Inc. 4Q 2025 Earnings Call - Act Three is AI: 2026 launch planned but revenue excluded from guidance
Warby Parker closed fiscal 2025 with solid growth and its first full year of net income, but the call felt like a dress rehearsal for something bigger. Management outlined an ambitious pivot into AI g...
- Warby Parker reported fiscal 2025 revenue of $871.9 million, up 13% year-over-year, with full-year adjusted EBITDA of $95 million, up 30%, and free cash flow of $44 million.
- The company delivered its first full year of net income in 2025 and ended the year with $286 million in cash, plus a $120 million credit facility (expandable to $175 million).
- Management announced Act Three: a planned launch of AI glasses in 2026 in partnership with Google and Samsung, positioning the company to move from traditional eyewear to intelligent eyewear.
- +13 more takeaways
ADTRAN Holdings Q4 2025 Earnings Call - Optical Surge Drives Revenue, Margins and Cash Flow Recovery
ADTRAN delivered a clean quarter of execution. Q4 revenue of $291.6 million beat expectations, driven by a 33% year-over-year leap in optical networking and broad-based growth across access, aggregati...
- Q4 revenue $291.6 million, up 20% year-over-year and 4% sequentially, above the high end of guidance.
- This was the sixth consecutive quarter of sequential growth and the fifth consecutive quarter of year-over-year improvement.
- U.S. revenue led the quarter, rising 31% year-over-year and 14% sequentially; non-U.S. revenue grew 12% year-over-year and declined 3% sequentially due to ordering patterns among large European customers.
- +17 more takeaways
Integra LifeSciences Q4 2025 Earnings Call - Quality and Supply Fixes Drive Cautious 2026 Recovery Plan
Integra closed 2025 having made visible progress on quality, compliance, and supply reliability, but the company is deliberately conservative about near-term growth while remediation and tariff uncert...
- Q4 2025 revenue was $435 million, adjusted EPS $0.83, both above the midpoint of guidance; sequential revenue improved by $33 million versus Q3.
- Full-year 2025 revenue was $1.635 billion, up 1.5% reported but down 0.7% on an organic basis, with Acclarent acquisition a key contributor to reported growth.
- Organic performance was hampered by quality remediation and supply constraints, notably in Tissue Technologies where Q4 revenue fell 12.8% (MediHoney remediation and tough Integra Skin comps were main drivers).
- +12 more takeaways
Hafnia Q4 2025 Earnings Call - Strong quarter and strategic push toward a TORM combination
Hafnia closed 2025 on a strong note, reporting Q4 net profit of $109.7 million and full-year net profit of $339.7 million. The company is returning capital aggressively, declaring an 80% payout for Q4...
- Q4 net profit $109.7 million, full-year 2025 net profit $339.7 million; Q4 was the strongest quarter of 2025 for Hafnia.
- Hafnia acquired 13.97% of TORM from Oaktree and is engaging with stakeholders to explore a potential combination, citing strategic, commercial and financial synergies.
- Dividend policy remains explicit and cash returns are large: 80% payout for Q4 equals $87.7 million, full-year dividends $271.7 million, implied yield about 10% for 2025.
- +13 more takeaways
Playtika Holding Corp Q4 2025 Earnings Call - D2C Hits $1 Billion Run Rate as SuperPlay Rewrites the Mix
Playtika closed 2025 with a clear strategic pivot: direct-to-consumer (D2C) and casual SuperPlay titles are reshaping revenue mix and cash generation, even as GAAP results took a big one-time hit from...
- Q4 2025 revenue was roughly $678.8 million, with Adjusted EBITDA of $201.4 million.
- Direct-to-consumer (D2C) reached a ~$1 billion annual run rate and represented 36.8% of Q4 revenue, a central part of management’s multi-channel strategy.
- Casual games now account for about 74% of Playtika’s revenue, reflecting a multi-year mix shift away from reliance on social casino titles.
- +12 more takeaways